Erratum: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes (Journal of Clinical Investigation (2004) 114 (280-290) DOI:10.1172/JCI200421583);Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

Journal of Clinical Investigation

Volumn 114, Issue 2, 2004, Pages 280-290

  Munn, David H ^a   Sharma, Madhav D ^a   Hou, Deyan ^a   Baban, Babak ^a   Lee, Jeffrey R ^a,b   Antonia, Scott J ^c   Messina, Jane L ^c   Chandler, Phillip ^a   Koni, Pandelakis A ^a   Mellor, Andrew L ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL DEXTRO TRYPTOPHAN; CD19 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL POPULATION; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; DENDRITIC CELL; GENE; GENE DISRUPTION; HUMAN; HUMAN TISSUE; IDO GENE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MICROENVIRONMENT; MOUSE; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR DRAINING LYMPH NODE;

EID: 4043092238     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200421583E1     Document Type: Erratum

References (82)

1. Smyth, MJ., Godfrey, D.I., and Trapani, J.A. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2:293-299.
2. Staveley-O'Carroll, K., et al. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 95:1178-1183.
3. Ochsenbein, A.F., et al. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:1058-1064.
4. Spiotto, M.T., et al. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737-747.
5. Wick, M., et al. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-238.
6. Gallimore, A., and Sakaguchi, S. 2002. Regulation of tumour immunity by CD25+ T cells. Immunology. 107:5-9.
7. Pardoll, D. 2001. T cells and tumours. Nature. 411:1010-1012.
8. Sotomayor, E.M., et al. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 98:1070-1077.
9. Cuenca, A., et al. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63:9007-9015.
10. Yu, P., Spiotto, M.T., Lee, Y., Schreiber, H., and Fu, Y.X. 2003. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med. 197:985-995.
11. Nguyen, L.T., et al. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:423-435.
12. Spiotto, M.T., Fu, Y.X., and Schreiber, H. 2003. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15:725-730.
13. Melief, C.J. 2003. Mini-review. Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33:2645-2654.
14. Steinman, R.M., Hawiger, D., and Nussenzweig, M.C. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685-711.
15. Moser, M. 2003. Dendritic cells in immunity and tolerance: do they display opposite functions? Immunity. 19:5-8.
16. Mellor, A.L., and Munn, D.H. 2003. Tryptophan catabolism and regulation of adaptive immunity. J. Immunol. 170:5809-5813.
17. Grohmann, U., Fallarino, F., and Puccetti, P. 2003. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24:242-248.
18. Munn, D.H., et al. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189:1363-1372.
19. Hwu, P., et al. 2000. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164:3596-3599.
20. Munn, D.H., et al. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 297:1867-1870.
21. Munn, D.H., et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 281:1191-1193.
22. Grohmann, U., et al. 2003. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. 198:153-160.
23. Grohmann, U., et al. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3:985-1109.
24. Gurtner, G.J., Newberry, R.D., Schloemann, S.R., McDonald, K.G., and Stenson, W.F. 2003. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 125:1762-1773.
25. Sakurai, K., Zou, J., Tschetter, J., Ward, J., and Shearer, G. 2002. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129:186-196.
26. Munn, D.H., and Mellor, A.L. 2004. IDO and tolerance to tumors. Trends Mol. Med. 10:15-18.
27. Uyttenhove, C., et al. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269-1274.
28. Taylor, M.W., and Feng, G. 1991. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5:2516-2522.
29. Mellor, A.L., Keskin, D.B., Johnson, T., Chandler, P., and Munn, D.H. 2002. Cells expressing indoleamine 2,3 dioxygenase inhibit T cell responses. J. Immunol. 168:3771-3776.
30. Lee, J.R., et al. 2003. Pattern of recruitment of immunoregulatory antigen presenting cells in malignant melanoma. Lab. Invest. 83:1457-1466.
31. Friberg, M., et al. 2002. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer. 101:151-155.
32. Huang, A.Y., et al. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961-965.
33. Dranoff, G., et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90:3539-3543.
34. + T cell responses in vivo. Int. Immunol. 8:351-358.
35. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoractive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
36. Hogquist, K.A., et al. 1994. T cell receptor antagonist peptides induce positive selection. Cell. 76:17-27.
37. Schwartz, R.H. 1996. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184:1-8.
38. Shrikant, P., Khoruts, A., and Mescher, M.F. 1999. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity. 11:483-493.
39. Fallarino, F., et al. 2002. Functional expression of indoleamine 2,3-dioxygenase by murine CD8alpha(+) dendritic cells. Int. Immunol. 14:65-68.
40. O'Keeffe, M., et al. 2002. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J. Exp. Med. 196:1307-1319.
41. Martin, P., et al. 2002. Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood. 100:383-390.
42. Karsunky, H., Merad, M., Cozzio, A., Weissman, I.L., and Manz, M.G. 2003. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J. Exp. Med. 198:305-313.
43. Homann, D., et al. 2002. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity. 16:403-415.
44. Nutt, S.L., Morrison, A.M., Dorfler, P., Rolink, A., and Busslinger, M. 1998. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 17:2319-2333.
45. Mikkola, I., Heavey, B., Horcher, M., and Busslinger, M. 2002. Reversion of B cell commitment upon loss of Pax5 expression. Science. 297:110-113.
46. Munn, D.H., Sharma, M.D., and Mellor, A.L. 2004. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172:4100-4110.
47. Vicari, A.P., et al. 2002. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med 196:541-549.
48. Almand, B., et al. 2000. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6:1755-1766.
49. Yang, L., et al. 2003. Cancer-associated immunodeficiency and dendriric cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111:727-735. doi:10.1172/JCI200316492.
50. Furumoto, K., Soares, L., Engleman, E.G., and Merad, M. 2004. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113:774-783. doi:10.1172/JCI200419762.
51. Hanson, H.L., et al. 2000. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13:265-276.
52. Nelson, D.J., et al. 2001. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 166:5557-5566.
53. Speiser, D.E., et al. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
54. Overwijk, W.W., et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198:569-580.
55. DeSilva, D.R., Urdahl, K.B., and Jenkins, M.K. 1991. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol. 147:3261-3267.
56. Powell, J.D., Lerner, C.G., and Schwartz, R.H. 1999. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162:2775-2784.
57. Grohmann, U., et al. 2000. IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha-dendritic cells via potentiation of the CD8 alpha+ subset. J. Immunol. 165:1357-1363.
58. Mellor, A.L., et al. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171:1652-1655.
59. Fallarino, F., et al. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4:1206-1212.
60. Pfefferkorn, E.R. 1984. Interferon γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. U. S. A. 81:908-912.
61. Gupta, S.L., et al. 1994. Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infect. Immun. 62:2277-2284.
62. Adams, O., et al. 2004. Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections. J. Virol. 78:2632-2636.
63. Bodaghi, B., et al. 1999. Role of IFN-gamma-induced indoleamine 2,3 dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162:957-964.
64. Bubnoff, D., et al. 2002. Fc-gamma RI induces the tryptophan degradation pathway involved in regulating T cell responses. J. Immunol. 169:1810-1816.
65. Fallarino, F., et al. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ 9:1069-1077.
66. Frumento, G., et al. 2002. Tryptophan-derived carabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196:459-468.
67. Terness, P., et al. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196:447-457.
68. Fearon, D.T., and Caxroll, M.C. 2000. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18:393-422.
69. Nutt, S.L., Heavey, B., Rolink, A.G., and Busslinger, M. 1999. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 401:556-562.
70. Bjorck, P., and Kincade, P.W. 1998. CD19+ pro-B cells can give rise to dendriric cells in vitro. J. Immunol. 161:5795-5799.
71. Izon, D., et al. 2001. A common pathway for dendritic cell and early B cell development. J. Immunol. 167:1387-1392.
72. Rissoan, M.C., et al. 2002. Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood. 100:3295-3303.
73. Corcoran, L., et al. 2003. The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells. J. Immunol. 170:4926-4932.
74. Iwasaki, A., and Kelsall, B.L. 1999. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190:229-239.
75. Asselin-Paturel, C., et al. 2001. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2:1144-1150.
76. Khong, H.T., and Restifo, N.P. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999-1005.
77. Borrello, I., Sotomayor, E.M., Cooke, S., and Levitsky, H.I. 1999. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10:1983-1991.
78. Bronte, V., et al. 1999. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162:5728-5737.
79. Mattei, S., et al. 1994. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer. 56:853-857.
80. Leong, S.P., Peng, M., Zhou, Y.M., Vaquerano, J.E., and Chang, J.W. 2002. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann. Surg. Oncol. 9:82-87.
81. Zelenika, D., et al. 1998. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J. Immunol. 161:1868-1874.
82. Scott, D., et al. 2000. Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Immunity. 12:711-720.